JW Therapeutics’s CAR-T Therapy Goes Public, Second Candidate after FosunKite Biotech
JW Therapeutics, the Suzhou-based cell company, applied for the market approval for the first CAR-T therapy injection. It is the second CAR-T therapy product candidate in the pipeline after Fosun Kite Biotech applied for Yescarta.
Cofounded by WuXi AppTec (603259:SH) and Juno Therapeutics (JUNO:Nasdaq), JW Therapeutics focuses on the research and development of CAR-T cellular therapy. The two pharmaceutical giants aim to establish a leading cellular therapy provider by injecting Juno’s technology of CAR-T (Chimeric antigen receptor T-cell) and TCR (T cell receptor) into WuXi AppTec’s R&D platform.
Earlier this June, JW Therapeutics closed the Series B funding round of USD 100 million. In March 2018, this pharmaceutical startup received USD 90 million in a Series A round from Sequoia, Temasek and other big-name investors.
Fosun and WuXi AppTec are pioneers to bring the cutting-edge biotechnological immunotherapy to the Chinese market. CAR-T therapy is expected to step into a commercial competition. After the aggressive pricing strategy towards the domestic PD-1 antibody, the public is concerned about the price of CAR-T therapy.
This text is a result of machine translation.
Related companies：
In-depth
Briefing Jun 13, 2022 09:44 AM
· Healthcare
Cro plate fell, and Wuxi apptec fell nearly 10%
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 22, 2021 03:11 PM
Healthcare
CRO ClinChoice Raises USD 150 Mn in Series E Round
2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.
Jul 05, 2022 08:17 PM
Briefing Mar 13, 2022 08:49 PM
· Financials
Capital group, an asset management institution, launched ETF products for the first time: buying Chinese stocks such as Guizhou Maotai, Yaoming biology and meituan
Healthcare
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Mar 31, 2021 11:38 AM
Briefing Mar 09, 2022 05:49 PM
Tianci materials: the net profit in the first two months increased by about 470% year-on-year
See more
Read next
Insight
In-depth
Insight
In-depth